Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Cash & Equivalents (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Cash & Equivalents for 16 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 17136.84% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, up 17136.84% year-over-year, with the annual reading at $13.1 million for FY2025, 17136.84% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $13.1 million at Plus Therapeutics, down from $13.3 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $21.3 million in Q3 2021, with the low at $74000.0 in Q1 2024.
  • Average Cash & Equivalents over 5 years is $11.5 million, with a median of $12.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 99.42% in 2024, then surged 17136.84% in 2025.
  • Over 5 years, Cash & Equivalents stood at $21.3 million in 2021, then decreased by 14.85% to $18.1 million in 2022, then plummeted by 52.79% to $8.6 million in 2023, then crashed by 99.11% to $76000.0 in 2024, then soared by 17136.84% to $13.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $13.1 million, $13.3 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.